Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019 Oxford, UK, and Cambridge, MA, US, 24 September 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) and collaborators will present new data analyses from the Phase 2 clinical trial of ridinilazole...
Category: News
SCYNEXIS Completes Last-Patient/Last-Visit Ahead of Schedule in the First Phase 3 Study (VANISH 303) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)
JERSEY CITY, N.J., Sept. 18, 2019 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced completion of the last-patient/last-visit in its Phase 3 VANISH 303 study, and that it expects to release top-line data earlier than previously reported. Ibrexafungerp (formerly SCY-078) is the first representative of...
Nabriva Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 18, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Chief Executive Officer Ted Schroeder will provide a company overview and business update at the 2019 Cantor...
Summit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship Focus on Improving Patient Outcomes
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship Focus on Improving Patient Outcomes New Classes of Targeted Antibiotics Support Stewardship and could Combat Resistance Oxford, UK, and Cambridge, MA, US, 18 September 2019 – Summit Therapeutics plc (NASDAQ: SMMT,...
Amplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients
SAN DIEGO, Sept. 16, 2019 /PRNewswire/ — Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that it has executed an exclusive worldwide license agreement with Novartis under which Amplyx has acquired the rights to the Phase 2 anti-BK virus (BKV) monoclonal antibody, MAU868,...
Amplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia
SAN DIEGO, Sept. 16, 2019 /PRNewswire/ — Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that two independent review committees completed their planned safety and efficacy assessment of data from 50% of the planned study population enrolled in the Company’s Phase 2 open-label clinical...
Amplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients
SAN DIEGO, Sept. 16, 2019 /PRNewswire/ — Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that it has executed an exclusive worldwide license agreement with Novartis under which Amplyx has acquired the rights to the Phase 2 anti-BK virus (BKV)...
FDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications
Designation Underscores Urgent Need for New Antifungals Targeting Multidrug-Resistant Pathogens
Paratek Mourns Passing of Co-founder Dr. Stuart Levy
BOSTON, Sept. 09, 2019 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) mourns the loss of Stuart Levy, M.D., who passed way last week. Dr. Levy co-founded the company more than two decades ago along with Dr. Walter Gilbert and was instrumental in the development of Paratek’s lead antibiotic, NUZYRA® and SEYSARA®.
Nabriva’s XENLETA™ (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) Now Available in the U.S.
First IV and oral antibiotic with novel mechanism of action approved by the FDA in nearly two decades, targets the most common CABP pathogens and supports antibiotic stewardship DUBLIN, Ireland, Sept. 09, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to...